Dry eye disease (DED) is a common ocular condition characterized by insufficient tear production or poor tear quality, leading to discomfort and visual disturbances. Lacritin is a small glycoprotein secreted by the lacrimal gland, which plays a crucial role in maintaining ocular surface health. It possesses multiple functions, including promoting tear film stability, supporting the growth and survival of corneal epithelial cells, and modulating the inflammatory response. Lacritin achieves these effects through interactions with specific cell surface receptors, such as syndecans and tropomyosin receptor kinase A (TrkA). Lacritin's influence on cellular homeostasis is evident in its ability to promote corneal epithelial cell proliferation, migration, and survival through mitogen-activated protein kinase (MAPK) signaling. Additionally, lacritin can activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which enhances cell survival and protects against apoptosis. In dry eye disease, lacritin levels are often reduced, suggesting a potential link between lacritin deficiency and the pathogenesis of the condition. Insufficient lacritin availability may compromise the integrity and function of the ocular surface, leading to epithelial cell damage, inflammation, and tear film instability. Given its multifaceted role in maintaining ocular surface health, lacritin holds promise as a therapeutic agent for dry eye disease. These strategies aim to restore lacritin levels and function, thereby improving tear film stability, enhancing corneal wound healing, and alleviating dry eye symptoms. 

IDH mutant cancers, characterized by mutations in the IDH1 and IDH2 genes, exhibit unique metabolic and microenvironmental characteristics. These mutations result in the production of 2-hydroxyglutarate (2-HG), which alters cellular metabolism and promotes tumor growth. IDH mutant cancers display metabolic rewiring, including increased glucose uptake and utilization through the pentose phosphate pathway and glycolysis. The tumor microenvironment in IDH mutant cancers undergoes changes that support tumor growth, such as immune cell activation and extracellular matrix remodeling. The interplay between metabolism and the tumor microenvironment is reciprocal, as metabolic alterations impact the microenvironment, and the microenvironment influences cancer cell metabolism. Understanding these features has important therapeutic implications, with ongoing research exploring targeted therapies and personalized treatment strategies. Overall, studying cancer metabolism and the tumor microenvironment in IDH mutant cancers provides insights into their development and progression, enabling the development of more effective treatments for patients.